UQ1 Stock Overview
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
uniQure N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.64 |
| 52 Week High | US$31.11 |
| 52 Week Low | US$12.29 |
| Beta | 0.95 |
| 1 Month Change | 0% |
| 3 Month Change | -4.44% |
| 1 Year Change | -40.10% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -40.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| UQ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.8% |
| 1Y | -40.1% | -15.8% | 1.0% |
Return vs Industry: UQ1 underperformed the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: UQ1 underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| UQ1 volatility | |
|---|---|
| UQ1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UQ1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine UQ1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 463 | Matt Kapusta | www.uniqure.com |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V. Fundamentals Summary
| UQ1 fundamental statistics | |
|---|---|
| Market cap | €899.25m |
| Earnings (TTM) | -€125.41m |
| Revenue (TTM) | €61.44m |
14.6x
P/S Ratio-7.2x
P/E RatioIs UQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UQ1 income statement (TTM) | |
|---|---|
| Revenue | US$61.43m |
| Cost of Revenue | US$125.95m |
| Gross Profit | -US$64.52m |
| Other Expenses | US$60.87m |
| Earnings | -US$125.39m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.68 |
| Gross Margin | -105.03% |
| Net Profit Margin | -204.12% |
| Debt/Equity Ratio | 24.3% |
How did UQ1 perform over the long term?
See historical performance and comparison